title: Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
abstract: Ovarian cancer (OC) is ranked as the eighth most common gynecological malignancy and is the leading cause of gynecological cancer-related deaths in women worldwide. The response to platinum- and taxane-based chemotherapy is very often poor, and targeted-therapeutics are currently being tested in patients with OC. Sorafenib is a non-selective multiple kinase inhibitor with proven antiproliferative effects in thyroid, renal and hepatocellular carcinoma. Sorafenib acts on vascular endothelial growth factor (VEGF) and on platelet-derived growth factor (PDGF) related pathways. It also influences the rat sarcoma proto-oncogene/rat fibrosarcoma protein kinase/mitogen activated protein kinase (RAS/RAF/MAPK) pathway and blocks tumor growth factor beta-1 (TGF-β-1)-mediated epithelial-mesenchymal transition (EMT). Sorafenib also acts at the epigenetic level altering the histone acetylation pattern. There have been phase I, II and III studies investigation sorafenib in OC. We review several trials in which sorafenib has been administered as single-agent or combined with other chemotherapeutics. Unfortunately, the effect of sorafenib was usually modest and complete response was rarely observed. Adverse effects occurred frequently, including rash, diarrhea, edema and weight gain. Sorafenib evidently blocks EMT in vitro. However, in the conducted trials, sorafenib was administered to patients with highly advanced tumors. We posit that blocking EMT may be more effective in early-stage disease. We also presume that sorafenib would work particularly well in the treatment of clear cell OC, since this type of OC has different molecular characteristics from usual OC and is less sensitive to standard chemotherapy. Furthermore, the combination of sorafenib with other multiple-kinase inhibiting agents, e.g. ABT-869, a targeted-agent mainly acting in the VEGF and PDGF pathways, should be investigated in further detail. It is probable that synergistic effects can be achieved.
authors.affiliation: Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, A-8036 Graz, Austria. johannes.haybaeck@medunigraz.at.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Smolle
authors.forename: Valentin
authors.initials: V
authors.lastname: Taucher
authors.forename: Edgar
authors.initials: E
authors.lastname: Petru
authors.forename: Johannes
authors.initials: J
authors.lastname: Haybaeck
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D002986:Clinical Trials as Topic; D018450:Disease Progression; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects / Q000235:genetics; D005260:Female; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D058990:Molecular Targeted Therapy; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D010671:Phenylurea Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000090063:Proto-Oncogene Mas; D015398:Signal Transduction / Q000187:drug effects; D000077157:Sorafenib; D053773:Transforming Growth Factor beta1 / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; C000715470:MAS1 protein, human; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D000090063:Proto-Oncogene Mas; D053773:Transforming Growth Factor beta1; D009536:Niacinamide; D000077157:Sorafenib
keywords: Ovarian cancer; review; sorafenib; targeted therapeutics; treatment